In today's ACT Brief, we examine the FDA's multi-domain transparency priorities, why radiopharmaceutical trials need redesigned infrastructure, and how AI can make enrollment more predictable.
News|Podcasts|July 29, 2026
ACT Brief: Data Pipeline Standardization for Real-Time Analysis, Sponsor Accountability Beyond Contracts, and Autoimmune Pipeline Expansion
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine how data standardization must precede real-time monitoring deployment, why contracts cannot transfer sponsor oversight responsibility, and a strategic acquisition broadening immunology development.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In
part two of his interview , Raviv Pryluk, CEO and co-founder of PhaseV, explained that the standardization and mapping work transforming raw trial data into analysis-ready formats is the actual bottleneck to real-time monitoring. AI is beginning to automate this transformation process fast enough to make continuous monitoring operationally feasible at scale without sacrificing data validation rigor. - In
part three of her contributed article series , Elizabeth Walsh described how clinical development depends on persistent interdependencies across phases, functions, and vendors that survive formal handoffs. Sponsor oversight cannot be contracted away; treating the CRO agreement as the point where sponsor responsibility ends creates invisible gaps where misalignment accumulates into vendor performance failures or regulatory findings. argenx completed the acquisition of Forte Biosciences for $77 per share in cash, representing approximately $2.2 billion equity value. FB102, a first-in-class anti-CD122 antibody showing clinical benefit in vitiligo (vit uh lie go) and celiac disease, brings potential multi-indication impact in autoimmune disease and broadens argenx's immunology mechanism portfolio.
That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine FDA input sought on early-phase ibogaine protocols, why mixed outsourcing models spread faster than oversight infrastructure, and a major partnership for a rare kidney disease treatment.
In today's ACT Brief, we examine practical guidance for clinical operations teams beginning AI adoption, how hierarchical endpoints better reflect treatment benefit, and why early-stage program failures signal smarter pipeline management.
In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
In today's ACT Brief, we examine what AI simulations surface in trial design, how RBQM delivers measurable financial returns, and three new FDA-approved treatments across hair loss, movement disorder, and bone disease.
In today's ACT Brief, we examine how AI is surfacing endpoint options beyond traditional design thinking, why sponsor oversight of outsourced work often fails on inspection despite being robust in practice, and a new combination drug for advanced kidney cancer.
Trending on Applied Clinical Trials Online
1
FDA Releases Transparency Roadmap Outlining Disclosure Priorities Across Drug Development and Regulatory Review
2
FDA Seeks Public Input on Early-Phase Clinical Trial Design for Ibogaine
3
Beyond the Molecule: Why Radiopharmaceutical Trials Require a New Operating Model
4
Mixed Outsourcing Models Are Spreading. Is Sponsor Oversight Keeping Up?
5